Date: July 30, 2026

Ref:- GHL/2026-27/EXCH/34

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('*Listing Regulations*')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('**GHL/Company'**) at its meeting held today i.e. *Thursday, July 30, 2026,* has *inter alia,* approved the following:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the First Quarter ended June 30, 2026 ('Financial Results').

   The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Exhibit-I** pursuant to Regulation 33 of the Listing Regulations.

2. Notice of 22nd Annual General Meeting (AGM) of the Company to be held on *Wednesday,* ***September 16, 2026 at 12:00*** *Noon* through Video Conferencing/Other Audio Video Means ('**VC/OAVM**') Facility.

3. Pursuant to Regulation 42 of Listing Regulations, has fixed the record date for the purpose of determining entitlement of the shareholders for the payment of final dividend for the financial year 2025-26, which shall be paid to the shareholders within 30 days from the date of declaration, if declared by the shareholders at the 22nd AGM.

Symbol	**Type of Security**	**Record date for payment of dividend**	**Purpose**
NSE: MEDANTA BSE: 543654	Equity	Friday, August 14, 2026	Payment of final dividend of Rs. 0.50/- per equity share for the financial year 2025-26, subject to approval of the shareholders at the ensuing AGM.

4. Appointment of Mr. Pradeep Kumar Singh designated as ‘Chief Digital Officer’ and one of the SMPs of the Company, basis the recommendation of Nomination and Remuneration Committee w.e.f. July 30, 2026. The details as required under Regulation 30 are enclosed as **Annexure-II**.

5. Approved the revised construction plan of Company’s upcoming hospital at Guwahati thereby increasing the proposed bed capacity from 400 beds to 650 beds. The details as required under Regulation 30 are enclosed as **Annexure-III** (in substitution of our earlier intimations in this regard dated April 28, 2025 and October 25, 2025).

The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.

The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 03:25 P.M.

Thanking You,

For Global Health Limited

RAHUL RANJAN Digitally signed by RAHUL RANJAN Date: 2026.07.30 15:37:55 +05'30'

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a

Walker Chandiok & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram - 122 002
India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') which includes GHL Employee Welfare Trust ('the Trust') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Tarun

Tarun Gupta
Partner
Membership No. 507892
UDIN: 26507892SZSYTI9786

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Place: Gurugram
Date: 30 July 2026

Global Health Limited
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN:L85110DL2004PLC128319
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org
Statement of standalone unaudited financial results for the quarter ended 30 June 2026

(₹ in millions, unless otherwise stated)

S No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Refer note 8	Unaudited	Audited
	Income				
I	Revenue from operations	10,787.23	9,606.29	8,821.56	37,093.78
II	Other income	240.60	358.05	231.39	1,064.08
	Total income	**11,027.83**	**9,964.34**	**9,052.95**	**38,157.86**
III	**Expenses**				
	Cost of materials consumed	2,261.59	1,886.44	1,921.63	7,858.56
	Purchases of stock-in-trade	-	(0.05)	25.59	19.43
	Changes in inventories of stock-in-trade	-	-	39.61	46.11
	Employee benefits expense	2,854.73	2,556.81	2,329.45	9,892.59
	Finance costs	158.90	134.64	56.58	410.85
	Depreciation and amortisation expense	546.04	522.08	334.08	1,709.07
	Retainers and consultants fee	1,659.19	1,559.40	1,092.81	5,445.32
	Other expenses	1,716.28	1,670.27	1,466.66	6,283.16
	Total expenses	**9,196.73**	**8,329.59**	**7,266.41**	**31,665.09**
IV	**Profit before exceptional items and tax**	**1,831.10**	**1,634.75**	**1,786.54**	**6,492.77**
	Exceptional items (refer note 4)	-	-	(195.92)	(3.77)
V	**Profit before tax**	**1,831.10**	**1,634.75**	**1,982.46**	**6,496.54**
VI	Tax expenses				
	Current tax	545.75	326.31	413.27	1,345.72
	Tax pertaining to earlier years	-	(7.85)	-	(33.30)
	Deferred tax charge/(credit)	(87.72)	74.98	49.55	222.11
VII	**Profit after tax**	**1,373.07**	**1,241.31**	**1,519.64**	**4,962.01**
VIII	**Other comprehensive income**				
	(i) Items that will not be reclassified to statement of profit or loss	(63.50)	47.94	3.01	46.64
	(ii) Equity instruments through OCI	-	(1.60)	-	(1.60)
	(iii) Income-tax relating to items that will not be reclassified to statement of profit or loss	15.98	(12.07)	(0.76)	(11.74)
	Total other comprehensive income	**(47.52)**	**34.27**	**2.25**	**33.30**
IX	**Total comprehensive income**	**1,325.55**	**1,275.58**	**1,521.89**	**4,995.31**
X	Paid-up equity share capital (face value of ₹ 2 each)	537.54	537.38	537.54	537.38
XI	Reserves (other equity)				39,588.28
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)				
	Basic (₹ per share)	5.11	4.62	5.66	18.46
	Diluted (₹ per share)	5.10	4.61	5.65	18.42

See accompanying notes to the standalone unaudited financial results

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Global Health Limited ★

Global Health Limited

Notes to the standalone unaudited financial results:

1 The above standalone financial results of Global Health Limited ('the Company') for the quarter ended on 30 June 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30 July 2026 and a limited review of the same has been carried out by the statutory auditors.

2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).

3 The Chief Operating Decision Maker (CODM) examines the Company's performance from a service perspective and has identified the healthcare services as single business segment.

4 **Exceptional items include:** **(₹ in millions)**

Particulars	**Quarter ended**	**Year ended**
	30 June 2025	**31 March 2026**
	Unaudited	**Audited**
Export Promotion Capital Goods (EPCG) obligation *(Refer point a below)*	(195.92)	(195.92)
Stamp duty on merger *(Refer point b below)*	-	(159.85)
Impact of new labour codes *(Refer point c below)*	-	352.00
Total	**(195.92)**	**(3.77)**

a During the quarter ended 30 June 2025, the Company reversed interest liability on EPCG amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Company. The Company had achieved the required export obligation within the prescribed timeline.

b Stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Company, however, during the year ended 31 March 2026, the Company reversed stamp duty amounting to ₹ 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application.

c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued Central Rules and related FAQs.

The Company had evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Company had presented such incremental impact, aggregating to ₹352.00 millions under 'Exceptional items'.

The Company continues to monitor the finalisation of the State Rules and any further government clarifications on other aspects of the Labour Codes.

5 The Company executed a Business Transfer Agreement (BTA) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore in April 2026.

6 **Employee benefits expense include:** **(₹ in millions)**

Particulars	**Quarter ended**			**Year ended**
	30 June 2026	**31 March 2026**	**30 June 2025**	**31 March 2026**
Employee share based payment expense	60.27	96.98	75.72	368.57

7 The standalone financial results also include the financial results of GHL Employee Welfare Trust.

8 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures for the full financial year and the unaudited figures up to the nine months ended 31 December 2025, which were subjected to limited review by the statutory auditors.

9 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

WALKER CHANDIOK & CO LLP CHARTERED ACCOUNTANTS

Place : Gurugram
Date : 30 July 2026

Dr. Naresh Trehan
Chairman and Managing Director

Global Health Limited

Walker Chandiok & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram - 122 002
India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Tarun

Tarun Gupta
Partner
Membership No.: 507892
UDIN: 26507892BNJNRL8796

WALKER CHANDIOK & CO LLP CHARTERED ACCOUNTANTS

Place: Gurugram
Date: 30 July 2026

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

S. No.	Name	Relationship with Holding Company
1	Global Health Patliputra Private Limited	Wholly owned subsidiary
2	GHL Pharma & Diagnostic Private Limited	Wholly owned subsidiary
3	GHL Hospital Limited	Subsidiary
4	Global Health Institute of Medical Sciences Foundation	Wholly owned subsidiary
5	Medanta Foundation - Poor and Needy Patients Welfare Trust	Trust

WALKER CHANDIOK & CO LLP
CHARTERED ACCOUNTANTS

Global Health Limited
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India
CIN:L85110DL2004PLC128319
Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org
Statement of consolidated unaudited financial results for the quarter ended 30 June 2026

S. No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		Unaudited	Refer note 7	Unaudited	Audited
	Income				
I	Revenue from operations	13,040.51	11,590.47	10,308.44	44,102.66
II	Other income	221.64	367.42	204.50	985.94
	Total income	**13,262.15**	**11,957.89**	**10,512.94**	**45,088.60**
III	**Expenses**				
	Cost of materials consumed	2,571.88	2,156.47	2,130.77	8,821.31
	Purchases of stock-in-trade	407.32	277.98	317.90	1,173.00
	Changes in inventories of stock-in-trade	(35.49)	30.84	(58.10)	(26.30)
	Employee benefits expense	3,192.73	2,846.97	2,564.04	10,961.08
	Finance costs	266.76	267.08	137.85	791.14
	Depreciation and amortisation expense	689.77	665.18	451.08	2,225.40
	Retainers and consultants fee	2,007.26	1,869.28	1,367.00	6,579.68
	Other expenses	2,029.29	1,971.30	1,716.91	7,402.91
	Total expenses	**11,129.52**	**10,085.10**	**8,627.45**	**37,928.22**
IV	**Profit before exceptional items and tax**	**2,132.63**	**1,872.79**	**1,885.49**	**7,160.38**
	Exceptional items (refer note 4)	-	-	(195.92)	10.21
V	**Profit before tax**	**2,132.63**	**1,872.79**	**2,081.41**	**7,150.17**
VI	**Tax expenses**				
	Current tax	545.75	326.31	413.27	1,345.72
	Tax pertaining to earlier years	-	(7.85)	-	(33.30)
	Deferred tax charge	14.36	137.80	78.32	297.07
VII	**Profit after tax**	**1,572.52**	**1,416.53**	**1,589.82**	**5,540.68**
VIII	**Other comprehensive income**				
	(i) Items that will not be reclassified to statement of profit or loss	(68.99)	51.81	3.11	50.86
	(ii) Equity instruments through OCI	-	(1.60)	-	(1.60)
	(iii) Income-tax relating to items that will not be reclassified to statement of profit or loss	17.36	(13.06)	(0.78)	(12.81)
	Total other comprehensive income	**(51.63)**	**37.15**	**2.33**	**36.45**
IX	**Total comprehensive income**	**1,520.89**	**1,453.68**	**1,592.15**	**5,577.13**
	Profit after tax attributable to:				
	(i) Owners of the Holding Company	1,587.27	1,439.88	1,590.09	5,564.60
	(ii) Non-controlling interests	(14.75)	(23.35)	(0.27)	(23.92)
	Other comprehensive income attributable to:				
	(i) Owners of the Holding Company	(51.62)	37.14	2.33	36.44
	(ii) Non-controlling interests	(0.01)	0.01	-	0.01
	Total comprehensive income attributable to:				
	(i) Owners of the Holding Company	1,535.65	1,477.02	1,592.42	5,601.04
	(ii) Non-controlling interests	(14.76)	(23.34)	(0.27)	(23.91)
X	Paid-up equity share capital (face value of ₹ 2 each)	537.54	537.38	537.54	537.38
XI	Reserves (other equity)				39,078.32
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)				
	Basic (₹ per share)	5.91	5.36	5.92	20.71
	Diluted (₹ per share)	5.90	5.35	5.91	20.66

See accompanying notes to the consolidated unaudited financial results

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Global Health Limited ★

Global Health Limited
Notes to the consolidated unaudited financial results:

1 The above consolidated unaudited financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group'), for the quarter ended 30 June 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30 July 2026. These consolidated unaudited financial results for the quarter ended 30 June 2026 have been reviewed by the statutory auditors.

2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).

3 The Chief Operating Decision Maker (CODM) examines the Group's performance from a service perspective and has identified the healthcare services as single business segment.

4 **Exceptional items include:** **(₹ in millions)**

Particulars	**Quarter ended**	**Year ended**
	30 June 2025	**31 March 2026**
Export Promotion Capital Goods (EPCG) Obligation *(Refer point a below)*	(195.92)	(195.92)
Stamp duty on merger *(Refer point b below)*	-	(159.85)
Impact of new Labour Codes *(Refer point c below)*	-	365.98
Total	**(195.92)**	**10.21**

a During the quarter ended 30 June 2025, the Holding Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Holding Company. The Holding Company had achieved the required export obligation within the prescribed timeline.

b Stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Holding Company, however during the year ended 31 March 2026, the Holding Company reversed stamp duty amounting to ₹ 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application.

c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued Central Rules and related FAQs.

The Group had evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Group had presented such incremental impact, aggregating to ₹365.98 millions under 'Exceptional items'.

The Group continues to monitor the finalisation of the State Rules and any further government clarifications on other aspects of the Labour Codes.

5 The Holding Company executed a Business Transfer Agreement (BTA) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore in April 2026.

6 **Employee benefits expense include:** **(₹ in millions)**

Particulars	**Quarter ended**			**Year ended**
	30 June 2026	**31 March 2026**	**30 June 2025**	**31 March 2026**
Employee share based payment expense	63.61	101.02	78.77	382.98

7 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures for the full financial year and the unaudited figures up to the nine months ended 31 December 2025, which were subjected to limited review by the statutory auditors.

8 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

For and on behalf of the Board of Directors of Global Health Limited

Place : Gurugram
Date : 30 July 2026

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Dr. Naresh Trehan
Chairman and Managing Director

Global Health Limited ★

Annexure II

Disclosure as mandated under Part- A (Para A) of Schedule III of Listing Regulations:

A. Appointments:

S. No.	Particulars	Details
1.	Reason for change *viz.* appointment, ~~resignation, removal, death or otherwise~~	Appointment of Senior Management Personnel (SMP).
2.	Date of appointment/~~re-appointment/cessation~~ (as applicable) & term of appointment	Mr. Pradeep Kumar Singh joined the Company as 'Chief Digital Officer' on July 11, 2026 and designated as SMP w.e.f. July 30, 2026. He will be in full time employment with the Company.
3.	Brief profile (in case of appointment)	Mr. Pradeep Kumar Singh is a seasoned technology leader with over 25 years of experience in technology leadership, digital transformation, product innovation, engineering, and enterprise platform development. Throughout his career, he has held leadership roles across leading global and Indian organizations, driving innovation, large-scale technology initiatives, and business transformation. He holds M.Tech. Degree from the Indian Institute of Technology, Roorkee, and B.Tech. Degree from the Institute of Engineering and Technology, Lucknow.
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA

Global Health Limited

Annexure-III

Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with relevant SEBI Circular(s)

S. No.	Particulars	Information Required
1.	Existing capacity	As on June 30, 2026, Medanta has existing capacity of 3,737 beds.
2.	Existing capacity utilization	Currently, Medanta Hospitals are operating in Gurugram, Indore, Ranchi, Lucknow, Patna and Noida.
3.	Proposed capacity addition	The Land Parcel allows construction of 650 bedded Hospital (as against earlier imitated 400 + beds).
4.	Period within which the proposed capacity is to be added	The proposed capacity will be added over the next 3-4 years in a phased manner.
5.	Investment required	The estimated project cost is of Rs. 970 crores.
6.	Mode of financing	The entire project is proposed to be funded from a mix of Internal accruals and Debt.
7.	Rationale	Proposed site is strategically located on National Highway 27, offering seamless connectivity across the entire North East region. With increase in FSI for the said project, and revised Guwahati bye-laws along with NBCS 2026 resulted in significant increase in available built up area for the hospital which can accommodate 650 beds. This expansion aims to strengthen healthcare infrastructure and will serve over 50 million people across Assam and its neighbouring states. Patients from these regions already travel to Guwahati and other metros for advanced care, making it the natural hub for a super specialty centre. In addition, the region faces a high burden of non-communicable diseases with limited tertiary care facilities Medanta's foray into the region will be transformative, bringing world-class medical expertise, cutting-edge technology and comprehensive care across more than 20+ super specialties, including transplants and advanced robotic procedures.